221 related articles for article (PubMed ID: 32130941)
1. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Sivakumaren SC; Shim H; Zhang T; Ferguson FM; Lundquist MR; Browne CM; Seo HS; Paddock MN; Manz TD; Jiang B; Hao MF; Krishnan P; Wang DG; Yang TJ; Kwiatkowski NP; Ficarro SB; Cunningham JM; Marto JA; Dhe-Paganon S; Cantley LC; Gray NS
Cell Chem Biol; 2020 May; 27(5):525-537.e6. PubMed ID: 32130941
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Structure-Activity Relationship Study of (
Manz TD; Sivakumaren SC; Ferguson FM; Zhang T; Yasgar A; Seo HS; Ficarro SB; Card JD; Shim H; Miduturu CV; Simeonov A; Shen M; Marto JA; Dhe-Paganon S; Hall MD; Cantley LC; Gray NS
J Med Chem; 2020 May; 63(9):4880-4895. PubMed ID: 32298120
[TBL] [Abstract][Full Text] [Related]
3. Expanding role of PI5P4Ks in cancer: A promising druggable target.
Arora GK; Palamiuc L; Emerling BM
FEBS Lett; 2022 Jan; 596(1):3-16. PubMed ID: 34822164
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.
Manz TD; Sivakumaren SC; Yasgar A; Hall MD; Davis MI; Seo HS; Card JD; Ficarro SB; Shim H; Marto JA; Dhe-Paganon S; Sasaki AT; Boxer MB; Simeonov A; Cantley LC; Shen M; Zhang T; Ferguson FM; Gray NS
ACS Med Chem Lett; 2020 Mar; 11(3):346-352. PubMed ID: 32184968
[TBL] [Abstract][Full Text] [Related]
5. Evolutionarily conserved structural changes in phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) isoforms are responsible for differences in enzyme activity and localization.
Clarke JH; Irvine RF
Biochem J; 2013 Aug; 454(1):49-57. PubMed ID: 23758345
[TBL] [Abstract][Full Text] [Related]
6. Selectively Targeting the Kinome-Conserved Lysine of PI3Kδ as a General Approach to Covalent Kinase Inhibition.
Dalton SE; Dittus L; Thomas DA; Convery MA; Nunes J; Bush JT; Evans JP; Werner T; Bantscheff M; Murphy JA; Campos S
J Am Chem Soc; 2018 Jan; 140(3):932-939. PubMed ID: 29232121
[TBL] [Abstract][Full Text] [Related]
7. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.
Powell JA; Lewis AC; Zhu W; Toubia J; Pitman MR; Wallington-Beddoe CT; Moretti PA; Iarossi D; Samaraweera SE; Cummings N; Ramshaw HS; Thomas D; Wei AH; Lopez AF; D'Andrea RJ; Lewis ID; Pitson SM
Blood; 2017 Feb; 129(6):771-782. PubMed ID: 27956387
[TBL] [Abstract][Full Text] [Related]
8. Development of Selective Phosphatidylinositol 5-Phosphate 4-Kinase γ Inhibitors with a Non-ATP-competitive, Allosteric Binding Mode.
Boffey HK; Rooney TPC; Willems HMG; Edwards S; Green C; Howard T; Ogg D; Romero T; Scott DE; Winpenny D; Duce J; Skidmore J; Clarke JH; Andrews SP
J Med Chem; 2022 Feb; 65(4):3359-3370. PubMed ID: 35148092
[TBL] [Abstract][Full Text] [Related]
9. Nuclear localizations of phosphatidylinositol 5-phosphate 4-kinases α and β are dynamic and independently regulated during starvation-induced stress.
Droubi A; Bulley SJ; Clarke JH; Irvine RF
Biochem J; 2016 Jul; 473(14):2155-63. PubMed ID: 27208178
[TBL] [Abstract][Full Text] [Related]
10. The function of phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ) explored using a specific inhibitor that targets the PI5P-binding site.
Clarke JH; Giudici ML; Burke JE; Williams RL; Maloney DJ; Marugan J; Irvine RF
Biochem J; 2015 Mar; 466(2):359-67. PubMed ID: 25495341
[TBL] [Abstract][Full Text] [Related]
11. The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy.
Lima K; Pereira-Martins DA; de Miranda LBL; Coelho-Silva JL; Leandro GDS; Weinhäuser I; Cavaglieri RC; Leal AM; da Silva WF; Lange APAL; Velloso EDRP; Griessinger E; Hilberink JR; Ammatuna E; Huls G; Schuringa JJ; Rego EM; Machado-Neto JA
Blood Cancer J; 2022 Nov; 12(11):151. PubMed ID: 36347832
[TBL] [Abstract][Full Text] [Related]
12. Concurrent targeting Akt and sphingosine kinase 1 by A-674563 in acute myeloid leukemia cells.
Xu L; Zhang Y; Gao M; Wang G; Fu Y
Biochem Biophys Res Commun; 2016 Apr; 472(4):662-8. PubMed ID: 26920060
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Inhibition of PIP4K2 Potentiates Venetoclax-Induced Apoptosis in Acute Myeloid Leukemia.
Lima K; Carvalho MFL; Pereira-Martins DA; Nogueira FL; de Miranda LBL; Nascimento MCD; Cavaglieri RC; Schuringa JJ; Machado-Neto JA; Rego EM
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069220
[TBL] [Abstract][Full Text] [Related]
14. The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K).
Aldred GG; Rooney TPC; Willems HMG; Boffey HK; Green C; Winpenny D; Skidmore J; Clarke JH; Andrews SP
RSC Med Chem; 2023 Oct; 14(10):2035-2047. PubMed ID: 37859710
[TBL] [Abstract][Full Text] [Related]
15. Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.
Willems HMG; Edwards S; Boffey HK; Chawner SJ; Green C; Romero T; Winpenny D; Skidmore J; Clarke JH; Andrews SP
RSC Med Chem; 2023 May; 14(5):934-946. PubMed ID: 37252102
[TBL] [Abstract][Full Text] [Related]
16. The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1.
Pearson RJ; Blake DG; Mezna M; Fischer PM; Westwood NJ; McInnes C
Cell Chem Biol; 2018 Sep; 25(9):1107-1116.e4. PubMed ID: 30017915
[TBL] [Abstract][Full Text] [Related]
17. Phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ), a lipid signalling enigma.
Giudici ML; Clarke JH; Irvine RF
Adv Biol Regul; 2016 May; 61():47-50. PubMed ID: 26710750
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.
Wu H; Wang W; Liu F; Weisberg EL; Tian B; Chen Y; Li B; Wang A; Wang B; Zhao Z; McMillin DW; Hu C; Li H; Wang J; Liang Y; Buhrlage SJ; Liang J; Liu J; Yang G; Brown JR; Treon SP; Mitsiades CS; Griffin JD; Liu Q; Gray NS
ACS Chem Biol; 2014 May; 9(5):1086-91. PubMed ID: 24556163
[TBL] [Abstract][Full Text] [Related]
19. Homology modeling and virtual screening for inhibitors of lipid kinase PI(4)K from Plasmodium.
Ren JX; Gao NN; Cao XS; Hu QA; Xie Y
Biomed Pharmacother; 2016 Oct; 83():798-808. PubMed ID: 27490781
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia.
Wang Y; Dou X; Jiang L; Jin H; Zhang L; Zhang L; Liu Z
Eur J Med Chem; 2019 Jun; 171():221-234. PubMed ID: 30925338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
